                         SEQUENCE LISTING

<110>  Kiniksa Pharmaceuticals, Ltd.
 
<120>  TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS

<130>  KPL-037WO

<150>  62/989,841
<151>  2020-03-15

<150>  63/002,325
<151>  2020-03-30

<150>  63/007,875
<151>  2020-04-09

<150>  63/009,267
<151>  2020-04-13

<150>  63/012,090
<151>  2020-04-18

<150>  63/016,043
<151>  2020-04-27

<150>  63/026,010
<151>  2020-05-16

<150>  63/029,160
<151>  2020-05-22

<150>  63/128,752
<151>  2020-12-21

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu 
            20                  25                  30          


Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Phe Asp Pro Glu Glu Asn Glu Ile Val Tyr Ala Gln Arg Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ile Val Gly Ser Phe Ser Pro Leu Thr Leu Gly Leu Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  2
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  2

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Thr Gly Ser Gly Ser Asn Ile Gly Ala Pro 
            20                  25                  30          


Tyr Asp Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 
        35                  40                  45              


Leu Ile Tyr His Asn Asn Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 
    50                  55                  60                  


Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 
65                  70                  75                  80  


Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Val Glu Ala Gly 
                85                  90                  95      


Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  3
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  3

Glu Leu Ser Ile His 
1               5   


<210>  4
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  4

Gly Phe Asp Pro Glu Glu Asn Glu Ile Val Tyr Ala Gln Arg Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  5
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  5

Val Gly Ser Phe Ser Pro Leu Thr Leu Gly Leu 
1               5                   10      


<210>  6
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  6

Thr Gly Ser Gly Ser Asn Ile Gly Ala Pro Tyr Asp Val Ser 
1               5                   10                  


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  7

His Asn Asn Lys Arg Pro Ser 
1               5           


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  8

Ala Thr Val Glu Ala Gly Leu Ser Gly Ser Val 
1               5                   10      


